Natriuretic Peptides for Risk Stratification of Patients with Acute Coronary Syndromes
Key result
Natriuretic peptides (BNP and NT-proBNP) provide independent and incremental prognostic value for mortality in patients with acute coronary syndromes.
Why the study?
Do natriuretic peptides (BNP and NT-proBNP) provide prognostic value for mortality in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes, including ST elevation myocardial infarction and no ST elevation…
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
May refine ACS mortality risk stratification beyond troponin; leaves open impact on therapy decisions.
Study Design
Type
Meta-Analysis
Structured PICO
Do natriuretic peptides (BNP and NT-proBNP) provide prognostic value for mortality in patients with acute coronary syndromes?
P
Population
Patients with acute coronary syndromes (ACS), including ST elevation myocardial infarction and no ST elevation ACS, with or without a history of previous heart failure or left ventricular dysfunction.
E
Exposure
Measurement of natriuretic peptides (BNP or NT-proBNP) at first patient contact or during hospital stay
O
Outcome
Prognostic value for mortalityhard clinical
BNP and NT-proBNP measurement provides independent prognostic value for mortality in ACS patients and should be integrated into routine evaluation.
Cite This Study
Galvani et al. (2004) conducted a meta-analysis in Acute coronary syndromes (ACS). Natriuretic peptides (BNP and NT-proBNP) was evaluated on Prognostic value for mortality. Natriuretic peptides (BNP and NT-proBNP) provide independent and incremental prognostic value for mortality in patients with acute coronary syndromes.